

BLUE SHIELD OF CALIFORNIA FOUNDATION

California Technology Assessment Forum

June 17, 2009

Luxe Hotel, Los Angeles

Summary of Panel Actions

1. Call to Order and Welcome to Guests - Ezra Davidson, M.D.
2. Voted to approve the minutes from March 11, 2009 CTAF meeting
3. Technology Assessment Criteria review – Leah Karliner, M.D, MAS
4. Eleven members of the CTAF panel were in attendance. This provided a quorum. The CTAF panel took the following actions:
 - A. Balloon Kyphoplasty as a Treatment for Vertebral Compression Fractures

The following recommendation was put before the CTAF panel for consideration:

- It is recommended that balloon kyphoplasty with PMMA *meets* CTAF criteria 1-5 for safety, effectiveness and improvement in health outcomes for the treatment of recent (<3 month old) osteoporotic vertebral compression fractures confirmed by MRI.
- It is further recommended that balloon kyphoplasty *does not meet* CTAF criteria 3-5 for safety, effectiveness and improvement in health outcomes for the treatment of chronic (>3 month old) osteoporotic, traumatic, or pathologic vertebral compression fractures.

Following Panel discussion and expert testimony, a motion was made by the CTAF Panel Discussion Leader to accept the recommendation as presented. The motion was seconded.

The CTAF panel voted six in favor of and two opposed to this recommendation. There were two abstentions and one recusal.

The motion carried.

- B. Carotid Artery Stenting

The following recommendation was put before the CTAF panel for consideration:

It is recommended that carotid artery angioplasty with stenting does not meet California Technology Assessment Forum TA Criterion 3 through 5 for improvement in health outcomes.

Following Panel discussion and expert testimony, a motion was made by the CTAF Panel Discussion Leader to accept the recommendation as presented. The motion was seconded.

The CTAF panel voted eight in favor and one opposed to this recommendation with one abstention.

The motion carried.

C. Assessing Cardiovascular Disease Risk with hs C-Reactive Protein

The following recommendation was put before the CTAF panel for consideration:

Measurement of hs-CRP does not meet CTAF criteria 3-5 for improvement in health outcomes compared with no testing.

Following Panel discussion and expert testimony, a motion was made by the CTAF Panel Discussion Leader accept recommendation

The CTAF panel vote was unanimous for this recommendation.

The motion carried.

D. Repetitive Transcranial Magnetic Stimulation for Treatment Resistant Depression

The following recommendation was put before the CTAF panel for consideration:

It is recommended that repetitive transcranial magnetic stimulation *does not* meet CTAF TA criteria 3-5 for efficacy and improvement in health outcomes in patients with treatment resistant depression.

Following Panel discussion a motion was made by the CTAF Panel Discussion leader to consider an alternative recommendation. The recommendation was that:

TA criterion 3 through 5 were met for the use of repetitive transcranial magnetic stimulation for treatment resistant depression. The motion was seconded.

The CTAF panel voted two for and seven opposed to this recommendation with one abstention.

The motion failed.

A motion was then made and seconded to accept the recommendation as stated in the draft assessment:

It is recommended that repetitive transcranial magnetic stimulation does not meet CTAF TA criteria 2-5 for efficacy and improvement in health outcomes in patients with treatment resistant depression.

The panel voted seven for and two opposed to this recommendation with one abstention. The motion carried..

The meeting was adjourned at 4:00 P.M. The next meeting of the California Technology Assessment Forum will be held on October 28, 2009 in San Francisco, CA.